drugset / Trial / NCT01911507
INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
Phase 1
Completed
35 enrolled
University of California, Davis
National Cancer Institute (NCI) · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of c-Met inhibitor INCB028060 and erlotinib hydrochloride when given together in treating patients with previously treated non-small cell lung cancer. C-Met inhibitor INCB028060 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2013-08-27
- Primary completion
- 2020-08-26
- Completion
- 2020-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capmatinib | Small molecule | — | Oral |
| Subject | Erlotinib | Small molecule | — | Oral |